ArticleMolecular and clinical oncology2017
Ovarian function following targeted anti-angiogenic therapy with bevacizumab.
Article in Molecular and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 37 citations in OpenAlex.
- Bevacizumab in Pediatric Neuro-Oncology.Current oncology (Toronto, Ont.) · 2025Review
- Gonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies.Human reproduction (Oxford, England) · 2025Review
- From Survival to Parenthood: The Fertility Journey After Childhood Cancer.Biomedicines · 2025Review
- Ovarian function in adolescents and young adults undergoing cancer treatment: biochemical and ultrasound marker analysis.Endocrine connections · 2025Article
- Fertility in young-onset colorectal patients with cancer: a review.The oncologist · 2024Review
- Menstrual Blood Stem Cells-Derived Exosomes as Promising Therapeutic Tools in Premature Ovarian Insufficiency Induced by Gonadotoxic Systemic Anticancer Treatment.International journal of molecular sciences · 2024Review
- Nucleic acid cancer vaccines targeting tumor related angiogenesis. Could mRNA vaccines constitute a game changer?Frontiers in immunology · 2024Review
- Primary ovarian insufficiency associated with lenvatinib therapy in a patient with hepatocellular carcinoma: A case report.Oncology letters · 2023Article
- [Physical long-term consequences of cancer].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2022Review
- Adolescent and young adult brain tumors: current topics and review.International journal of clinical oncology · 2022Review
- Premature ovarian insufficiency: pathogenesis and therapeutic potential of mesenchymal stem cell.Journal of molecular medicine (Berlin, Germany) · 2021Review
- Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient: A CARE-compliant case report.Medicine · 2019Article
- Carvacrol and Thymol Modulate the Cross-Talk between TNF-Oxidative medicine and cellular longevity · 2019Article
- Reproductive Function and Outcomes in Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Review.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Review
- New Agents, Emerging Late Effects, and the Development of Precision Survivorship.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Review
- Palmar fasciitis with polyarthritis-associated ovarian cancer: Case report and literature review.Molecular and clinical oncology · 2018Article
- Anti-Angiogenic Alternative and Complementary Medicines for the Treatment of Endometriosis: A Review of Potential Molecular Mechanisms.Evidence-based complementary and alternative medicine : eCAM · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improvements in cancer therapy have enabled further insight into the long-term effects of treatment, including the highly prevalent gonadal failure. The focus of treatment has been shifted to the preservation of fertility, which may be achieved by preventing ovarian toxicity. To this end, new molecular-targeted agents, including monoclonal antibodies, have been developed and used in a standard procedure for managing different cancers. However, the prolonged antitumor activity of these drugs may cause the emergence of new toxic effects. The aim of the present review was to discuss the leading toxic effect of the anti-angiogenic agent bevacizumab on ovarian function in female patients of reproductive age, which may be observed and expected during in clinical practice. The majority of bevacizumab-induced side effects are expected to be transient and eliminated within the anticipated drug clearance time frame; however, fundamental investigations on these effects are required for generating more evidence-based practice guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.